Epilepsy - Drug Pipeline Analysis and Market Forecasts to 2015

GlobalData, the industry analysis specialist’s new report, “Epilepsy – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global epilepsy market. The report identifies the key trends shaping and driving the global epilepsy market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global epilepsy sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The Scope of the report includes:I37
- Annualized global epilepsy market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action includes Voltage-gated ion channels (α2-δ subunit of the voltage-gated Ca++ channel; the α subunits of voltage-gated Na+ channels; K+ channels); Enhancement of GABA-mediated transmissions, Acetylcholine agonists, NMDA targetters, Benzodiazepines.
- Analysis of the current and future market competition in the global epilepsy market. Key market players covered are Pfizer, UCB Pharma, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Abbott Laboratories, Sanofi-Aventis SA, and Cephalon.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with epilepsy.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global epilepsy market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global epilepsy market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global epilepsy market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS


1.1 LIST OF TABLES


1.2 LIST OF FIGURES


2 EPILEPSY MARKET: MARKET CHARACTERIZATION

2.1 Overview
2.2 Epilepsy Market Size
2.3 Epilepsy Market Forecast and CAGR
2.4 Drivers and Barriers for the Epilepsy Market
  2.4.1 Drivers for the Epilepsy Market
  2.4.2 Barriers for the Epilepsy Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 EPILEPSY MARKET: COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Epilepsy Market
  3.3.1 Lyrica (Pregabalin)
  3.3.2 Gabitril (Tiagabine Hcl)
  3.3.3 Banzel (Rufinamide)
  3.3.4 Vimpat (Lacosamide)
  3.3.5 Felbatol (Felbamate)
  3.3.6 Sabril (Vigabatrin)
3.4 Key Takeaway

4 EPILEPSY MARKET: PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
  4.2.1 Technology Trends Analytic Framework
4.3 Epilepsy Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
  4.4.1 Stedesa (Eslicarbazepine Acetate)
  4.4.2 Comfyde™ (Carisbamate)
  4.4.3 Retigabine
  4.4.4 Brivaracetam
  4.4.5 Ganaxolone
4.5 Epilepsy Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Epilepsy Pipeline – Pipeline by Clinical Phases of Development
  4.6.1 Epilepsy Therapeutics – Regulatory and Phase III Clinical Pipeline
  4.6.2 Epilepsy Therapeutics – Phase II Clinical Pipeline
  4.6.3 Epilepsy Therapeutics – Phase I Clinical Pipeline
  4.6.4 Epilepsy Therapeutics – Preclinical Pipeline
4.7 Discontinued / Suspended Drugs for Epilepsy
4.8 Key Takeaway

5 EPILEPSY MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION


6 EPILEPSY MARKET: FUTURE PLAYERS IN THE EPILEPSY MARKET

6.1 Introduction
6.2 GlaxoSmithKline plc
  6.2.1 Overview
  6.2.2 CNS Portfolio
  6.2.3 Epilepsy Portfolio
6.3 UCB Pharmaceuticals
  6.3.1 Overview
  6.3.2 CNS Portfolio
  6.3.3 Epilepsy Product Portfolio
6.4 Johnson & Johnson
  6.4.1 Overview
  6.4.2 CNS Portfolio
  6.4.3 Epilepsy Product Portfolio
6.5 Pfizer Inc.
  6.5.1 Overview
  6.5.2 CNS Portfolio
  6.5.3 Epilepsy Product Portfolio
6.6 Sepracor Inc
  6.6.1 Overview
  6.6.2 CNS Portfolio
6.7 Supernus Pharmaceuticals Inc
  6.7.1 Overview
  6.7.2 CNS Portfolio
  6.7.3 Epilepsy Product Portfolio

7 EPILEPSY MARKET: APPENDIX

7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panel validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

1.1 LIST OF TABLES

Table 1: Global Cystic Fibrosis Therapeutics Market, Revenue ($m), 2000–2008
Table 2: Global Cystic Fibrosis Therapeutics Market, Revenue ($m), 2009–2015
Table 2: Major Marketed Products Comparison in the Epilepsy Market, 2009
Table 3: Epilepsy Therapeutics – Most Promising Drugs Under Clinical Development, 2009
Table 4: Epilepsy Therapeutics – Phase III Clinical Pipeline, 2009
Table 5: Epilepsy Therapeutics – Phase II Clinical Pipeline, 2009
Table 6: Epilepsy Therapeutics – Phase I Clinical Pipeline, 2009
Table 7: Epilepsy Therapeutics – Preclinical Pipeline, 2009
Table 8: GlaxoSmithKline – CNS Marketed Products, 2009
Table 9: GlaxoSmithKline – CNS Pipeline Products, 2009
Table 10: UCB Pharma – CNS Marketed Products, 2009
Table 11: UCB Pharma – CNS Pipeline Products, 2009
Table 12: Johnson & Johnson – CNS Marketed Products, 2009
Table 13: Johnson & Johnson – CNS Pipeline Products, 2009
Table 14: Pfizer – CNS Marketed Products, 2009
Table 15: Pfizer – CNS Pipeline Products, 2009
Table 16: Sepracor Inc – CNS Marketed Products, 2009
Table 17: Sepracor Inc – CNS Pipeline Products, 2009
Table 18: Supernus Pharmaceuticals – CNS Pipeline Products, 2009

1.2 LIST OF FIGURES

Figure 1: Global Epilepsy Market Revenue ($m) 2000–2015
Figure 2: Opportunity and Unmet Need, 2009
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Epilepsy, 2009
Figure 4: Technology Trends Analytic Framework of the Epilepsy Pipeline, 2009
Figure 5: Technology Trends Analytic Framework of the Epilepsy Pipeline – Description, 2009
Figure 6: Epilepsy Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2009
Figure 7: Epilepsy Pipeline by Phase of Clinical Development, 2009
Figure 8: Implications for Future Market Competition in the Epilepsy Market, 2009
Figure 9: Epilepsy Therapeutics Market – Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model
GlaxoSmithKline plc
UCB Pharmaceuticals
Johnson & Johnson
Pfizer Inc
Sepracor Inc
Supernus Pharmaceuticals Inc
Skip to top